Bacteria and carcinogenesis
It is estimated that over 15% of malignancies worldwide can be attributed to infections or about 1.2 million cases per year. Pisani et al. [
1] Infections involving viruses, bacteria and schistosomes have been linked to higher risks of malignancy. Although viral infections have been strongly associated with cancers [
2,
3] bacterial associations are significant. For example, convincing evidence has linked
Helicobacter pylori with both gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma [
4‐
6], however other species associated with cancers include:
Salmonella typhi and gallbladder cancer [
7‐
10],
Streptococcus bovis and colon cancer [
11‐
14] and
Chlamydia pneumoniae with lung cancer [
15‐
17]. Important mechanisms by which bacterial agents may induce carcinogenesis include chronic infection, immune evasion and immune suppression [
18].
It has been shown that several bacteria can cause chronic infections or produce toxins that disturb the cell cycle resulting in altered cell growth [
15,
16,
19]. The resulting damage to DNA is similar to that caused by carcinogenic agents as the genes that are altered control normal cell division and apoptosis [
20,
21]. Processes that encourage the loss of cellular control may be tumor initiators (directly causing mutations) or promoters (facilitating mutations). Tumorigenesis is initiated when cells are freed from growth restraints, later promotion results when the immune system is evaded favoring further mutations and increased loss of cell control. As the tumor proliferates an increased blood supply is needed resulting in the organization of blood vessels or angiogenesis. Subsequent invasion occurs if the tumor breaks down surrounding tissues. The worst outcome is metastasis which results when cells break away from the tumor and seed tumors at distant sites [
8].
The immune system is an important line of defense for tumor formation of malignancies that express unique antigens. Certain bacterial infections may evade the immune system or stimulate immune responses that contribute to carcinogenic changes through the stimulatory and mutagenic effects of cytokines released by inflammatory cells. These include reactive oxygen species (ROS), [
22,
23], interleukin-8 (IL-8) [
11], cyclooxygenase-2 (COX-2), [
24], reactive oxygen species (ROS) and nitric oxide (NO) [
25]. Chronic stimulation of these substances along with environmental factors such as smoking, or a susceptible host appears to contribute significantly to carcinogenesis.
Salmonella typhi and gallbladder cancer
Worldwide annual incidence of gallbladder cancer (GC) is 17 million cases with high incidence rates in certain populations. The malignancy is usually associated with gallstone disease, late diagnosis, unsatisfactory treatment, and poor prognosis. The five-year survival rate is approximately 32 percent for lesions confined to the gallbladder mucosa and one-year survival rate of 10 percent for more advanced stages [
26]. Over 90 percent of gallbladder carcinomas are adenocarcinoma [
27] involving gallstones in 78% – 85% of cases [
26].
There are several risk factors for gallbladder cancer. The main associated risk factors include cholelithiasis (especially untreated chronic symptomatic gallstones), obesity, reproductive factors, environmental exposure to certain chemicals, congenital developmental abnormalities of the pancreatic bile-duct junction and chronic infections of the gallbladder [
26,
28]. The interplay of genetic susceptibility, lifestyle factors and infections in gallbladder carcinogenesis is still poorly understood [
29], however a link has been specifically proposed between chronic bacterial infections of the gallbladder and
Salmonella typhi [
26].
The strongest epidemiological evidence of bacterial oncogenic potential, aside of
Helicobacter pylori, concerns
S. typhi. Infection with this bacterium of typhoid, can lead to chronic bacterial carriage in the gallbladder [
30]. Recent epidemiological studies have shown that those who become carriers of
S. typhi have 8.47 times the increased risk of developing carcinoma of the gallbladder compared with people who have had acute typhoid and have cleared the infection [
26]. These findings agreed with earlier investigations by Welton et al. [
31] and Caygill [
30].
A case-control study by Welton et al [
31] compared those who experienced acute infection with
S. typhi to those who subsequently became chronic carriers following the 1922 typhoid outbreak in New York. Carriers were six times more likely to die of hepatobiliary carcinoma than matched controls. Additional evidence was found in an analysis of the 1964 typhoid outbreak in Aberdeen [
30]. Their findings also suggested a strong association between chronic carrier status and hepatobiliary carcinoma. These studies also agreed, people who contracted typhoid but did not become carriers were not at higher risk of cancer [
8,
26,
30,
31].
The highest incidence of gallbladder cancer (GC) in the world is among populations of the Andean area, North American Indians, and Mexican Americans. In Europe, the highest rates are found in Poland, the Czech Republic and Slovakia. The high rates observed in Latin America are primarily in populations with high levels of Indian mixture [
32]. This evidence supports the notion that increased susceptibility to gallbladder cancer depends on genetic factors that predispose people to gallbladder cancer either as primary factors, or secondarily as promoters by favoring the development of cholesterol gallstones. The highest mortality rates are in South America, (3.5–15.5 per 100,000) and among Mexican Americans [
26]. Incidence rates of GC in various ethnic groups in the USA confirmed the worldwide pattern, as GC was substantially more frequent among Hispanic than non-Hispanic white women and men. Interestingly, compared to non-Hispanic whites an excess of GC was also reported among American Indians in New Mexico, in agreement with the excess in incidence rates reported for American Indians and Alaskan Natives [
33]. The malignancy is 3 times higher, however, among women than men in all populations [
26].
Two main pathways to GC exist worldwide. The predominant pathway involves gallstones and resultant cholecystitis and affects women to a greater extent than men. The risk of developing gallstones in response to environmental factors is genetically determined, as shown by the marked tendency of gallstones to cluster in families [
34]. The other pathway involves an anomalous pancreatobiliary duct junction (APBDJ), a congenital malformation of the biliary tract that is more frequent in Japan, Korea, and possibly China, than in Western countries [
28]. In APBDJ, the premature junction of common bile and pancreatic ducts results in regurgitation of pancreatic juice into the gallbladder, leading to bile stasis and inflammation, though generally less severe than that resulting from gallstones [
28].
Currently the prevention of gallbladder cancer in high risk populations depends upon the diagnosis of gallstones and removal of the gallbladder. Indeed, a strong inverse association between number of cholecystectomies and GC incidence and mortality rates can be found in many countries. The increase of GC mortality reported in Chile in the 1980s was related to decreased rates of cholecystectomies [
35]. Increased rates led to the removal of gallbladders at risk, and a reduction of GC incidence and mortality in Europe and the United States [
36].
Unfortunately, information about the genetic changes involved in gallbladder carcinogenesis is limited. Most studies have focused on gene abnormalities and deletions ("loss of heterozygosity") at chromosomal regions harboring known or putative tumor suppressor genes [
28]. It appears, however, that
TP53 inactivation has an important and early role in gallbladder carcinoma associated with gallstones and chronic inflammation. This inactivation would abrogate the tumor suppressor function of the p53 protein resulting in impairments in cell cycle control, cellular repair and apoptosis.
In contrast,
KRAS mutations are frequent and early events in tumors associated with APBDJ [
28] but detected less often in gallbladder carcinomas associated with gallstones. KRAS is an oncogene that encodes a protein that is a member of the small GTPase family. A mutation in this gene results in an abnormal protein implicated in several malignancies, including lung adenocarcinoma, ductal carcinoma of the pancreas and colorectal carcinoma among others.
Chlamydophila pneumoniae and lung cancer
Lung cancer is the leading cause of cancer death in the United States and many countries in the Western world. In 2002, the most recent year for which statistics are available, 90,121 males and 67,509 females died from lung cancer [
37]. About 6 out of 10 people with lung cancer die within 1 year of finding out they have lung cancer. Between 7 and 8 will die within 2 years [
38]. Although patients may experience a partial or complete response to treatment, most patients relapse and die. Increased dosage of chemotherapy or length of treatment has not been beneficial [
39].
Chlamydophila (formerly
Chlamydia) pneumoniae infection has been implicated in several chronic lung diseases by serology and direct antigen detection. Acute lower respiratory tract infection caused by
C. pneumoniae seems often to precede attacks of asthma in both children and adults but is also involved in some exacerbations of chronic bronchitis. More importantly it seems to be strongly associated with chronic obstructive lung disease irrespective of exacerbation status. Moreover, persistently elevated
C. pneumoniae antibody titers have been observed in sarcoidosis and lung cancer [
40].
C. pneumoniae is a Gram-negative bacillus and an intracellular parasite that causes respiratory infection in more than 50% of adults. The route of transmission is usually by aerosol and in most cases these infections are mild. The bacterium is, however, an important cause of pneumonia, bronchitis, sinusitis, rhinitis and chronic obstructive pulmonary disease [
41]. Respiratory infections from
C. pneumoniae vary in different countries and populations, being endemic in the United States and epidemic in Scandinavian countries [
19].
After acute infection the
C. pneumoniae intracellular life cycle is characterized by the development of metabolically inert (and thus antibiotic resistant) atypical "persistent" inclusions. These inclusions contain increased quantities of chlamydial heat shock protein 60, a highly immunogenic protein implicated in the pathogenesis of chronic chlamydial infections. The resulting clinical course is acute symptomatic illness followed by chronic respiratory symptoms. Research also suggests that persistent
C. pneumoniae inflammation correlates with increased risk of lung cancer [
16,
17,
19]. Prospective and retrospective studies both report that individuals with elevated IgA antibody titers to this organism have 50% to 100% increased lung cancer risk [
15].
In a study by Kocazeybek et al. [
19] the relationship between chronic
C. pneumoniae infection and lung carcinoma was examined. A total of 123 patients who were smokers and diagnosed with lung carcinoma based on clinical and laboratory (radiological, cytological) findings were examined. 101 (82.1%) of the cases were male. 70 had small-cell, 28 squamous-cell and 7 large-cell carcinomas, while 18 had adenocarcinoma. 123 healthy controls were matched to the cancer patients by age, gender, duration of smoking and locality.
Blood samples (5 ml) were withdrawn at the time of diagnosis (or enrollment for controls) and 1 month later. Values between IgG ≥512 and IgA ≥40 were set as the criteria for chronic C. pneumoniae infections. In male patients with lung carcinoma, IgG antibody titers of ≥512 and IgA antibody titers of ≥40 were found at a higher rate than in the control group, however, this ratio was not significant for female patients. These elevations in antibody titers were found in a total of 62 (50.4 %) cases, 54% of the male patients and 36% of the female patients. Chronic C. pneumoniae infections were seen statistically more often in male patients with carcinoma who were aged 55 years or younger than in controls (P < 0.001). No difference was reported between male patients with lung carcinoma over age 55 and controls or in blood titers between female patients and controls.
The relationship between
C. pneumoniae infection and lung carcinoma was studied by Littman et al. [
42] in a large prospective case-control study to investigate whether IgA antibody titers to
C. pneumoniae were associated with lung cancer risk. A total of 508 pairs were enrolled and included both current and former smokers. Serum was collected at baseline and annually thereafter. Antibody determinations of each lung cancer subject and matched control were tested simultaneously in the same titration series in a blinded fashion.
C. pneumoniae titers (IgA or IgG) ≥16 were considered seropositive, which was consistent with the cutoff used in other studies. Subjects were matched by age, gender, and smoking status at baseline. The median age of cases and controls was 59 years and about half were women. All subjects were also examined for demographic, lifestyle, dietary, and racial and ethnic factors. Lung cancer subjects had a heavier smoking history than controls.
After adjusting for a history of chronic bronchitis or emphysema, lung cancer subjects were more likely to have IgA titers ≥16 (55.4% vs. 51.3%) and ≥256 (5.1% vs. 2.5%) to C. pneumoniae than controls. Individuals with antibody tiers IgA ≥16 had 1.2 times the risk of lung cancer (95% confidence interval, 0.9–1.6) compared to those with lower titers. Investigators reported a significant trend (P = 0.007) of increasing odds ratios with increasing IgA titers primarily due to an odds ratio of 2.8 (95% confidence interval, 1.1–6.7) associated with titers ≥256. Elevated IgA was reported with squamous cell carcinomas and to a lesser extent, for small cell carcinomas and adenocarcinomas. There was no evidence of a stronger association with elevated IgG titers however. Subjects with race not classified as White or Black were more likely to have IgA titers ≥16. No significant differences in seropositivity were found, however, based on smoking behaviors.
Streptococcus bovis and colorectal cancer
Colorectal cancer (CRC) is a common malignancy in developed countries and is the 3rd most common cancer in the United States [
38]. Greater than 80% occur sporadically [
43]. The American Cancer Society estimates that there will be about 104,950 new cases of colon cancer and 40,340 new cases of rectal cancer in 2005 in the United States. Combined, they will cause about 56,290 deaths. The risk of colon cancer increases after the age of 40 and rises exponentially from the ages of 50 to 55. In fact, more than 9 out of 10 people found to have colorectal cancer are older than 50 [
38].
Survival of CRC is related to the stage of disease at the time of the initial diagnosis. Between 1985 and 1997, death rates of colon cancer in the United States declined slightly due to earlier detection of primary tumors, via stool blood tests, sigmoidoscopy, colonoscopy, and screening tests for serum carcinoembryonic antigen concentration (CEA) [
44]. The 5-year survival rate for CRC patients is greater than 90% when tumors are detected at a localized early stage. After the cancer has spread regionally and involves adjacent organs or lymph nodes, the rate drops to 40–65%; survival is less than 10% for patients with distant metastases. Therefore, there is an urgent need to develop effective treatment strategies to reduce morbidity and mortality. Surgery is currently the primary treatment modality for this disease. By the time the patient presents with recurrent symptoms, however, the disease is rarely curable by surgery even when combined with other therapies [
45].
Several species of bacteria have been linked to chronic infections of the colon and increased risk of colon cancer including
Escherichia coli [
46] and several streptococci [
47,
48]. Recent studies, however, have validated earlier findings of an association between colon cancer and
Streptococcus bovis [
11,
12]. As early as 1951, McCoy and Mason [
49] suggested a relationship between colonic carcinoma and the presence of infectious endocarditis. It was not until 1974 [
50] that the association of
Streptococcus bovis and colonic neoplasia was recognized, as 25–80% of patients who presented with a
S. bovis bacteremia had a colorectal tumor. The incidence of
S. bovis associated colon cancer has been determined as 18% to 62% [
14].
S. bovis is a normal inhabitant of the human gastrointestinal tract that can cause bacteremia, endocarditis, and urinary infection [
51]. Although
S. bovis is the 2
nd greatest cause of infectious endocarditis from streptococci [
50], it is frequently associated with gastrointestinal lesions, especially carcinoma of the colon [
12,
51‐
53]. Notably, the colonic neoplasia may arise years after the presentation of the condition of bacteremia or infectious endocarditis [
12].
A retrospective review of forty-five documented cases of
S bovis bacteremia was conducted by Gold et al. [
12]. Subjects were identified by a search of computerized bacteriology records from one tertiary referral hospital and 1 community hospital located in the same city. Patient records were reviewed to identify the presence of colonic neoplasia, the use of gastrointestinal endoscopy, and the presence of gastrointestinal or extraintestinal malignancies. Seventeen patients (41% of adult patients) underwent colonoscopy. Colonic neoplasia was present in 16 patients (39% of adults). Invasive cancer was present in 13 patients (32% of adults), 8 of these had malignant lesions arising within the gastrointestinal tract, 3 affecting the colon and 5 patients had extraintestinal malignancies. The authors concluded that
S. bovis bacteremia was associated with both colonic neoplasia and extracolonic malignancy.
It has been demonstrated that
S. bovis or its wall extracted antigens (WEA) were able to promote carcinogenesis in rats [
12]. In one of these investigations a total of 10 adult rats received i.p. injections of the carcinogen azoxymethane (AOM) (15 mg/kg body weight) once per week for 2 weeks. Fifteen days after the last injection of AOM (week 4) the rats were randomly divided into three groups. Twice per week during 5 weeks, the rats received, by gavage either
S. bovis (10
10 bacteria Group I), WEA (100 μg Group II) and controls (Group III).
One week after the last gavage (week 10), they found that administration of either S. bovis or its antigens promoted the progression of preneoplastic lesions. There were increased formations of hyperproliferative aberrant colonic crypts, enhanced expression of proliferation markers and increased production of IL-8 in the colonic mucosa. Normal rats treated with the bacteria did not develop hyperplastic colonic crypts, however. The authors concluded that S. bovis exerts its pathological activity in the colonic mucosa only when preneoplastic lesions are established.
Under identical experimental conditions Streptococcus gordonii was substituted for S. bovis. The number of preneoplastic lesions in the colon of S. gordonii-treated rats was similar to rats treated with AOM alone (22 ± 2). The authors suggested that S. bovis and its wall extracted antigens, unlike S. gordonii, act as promoters of carcinogenesis in a chemically-induced animal model.
In another investigation Biarc et al. [
11] isolated 12
S. bovis cell-associated proteins (S300) and WEA. Cells of the human colonic epithelial cell line Caco-2 originally derived from an adenocarcinoma were grown to confluence and allowed to differentiate. These cells were stimulated with 200 ul of either
S. bovis WEA (50 μg/ml) or cell-associated proteins S300 (100 μl).
The purified S300 fraction was able to trigger the human cell line and rat colonic mucosa to release chemokines (human IL-8 or rat CINC/GRO) and prostaglandin E2 (PgE2). The 12 S. bovis proteins were highly effective in the promotion of pre-neoplastic lesions in azoxymethane treated rats. In fact the S300 proteins were able to induce a 5-fold increase in PGE2 secretion from Caco-2 cells, as compared with cells stimulated with WEA. The study found that PGE2 release in the human cells correlated with an over-expression of cyclooxygease-2 (COX-2).
Evidence has shown that over-expression of COX-2 has a major role in mucosal inflammation [
47] and is associated with inhibition of apoptosis [
54] and enhancement of angiogenesis [
55], which favor cancer initiation and development. It was reported by Biarc et al. [
11] that
S. bovis proteins also promoted cell proliferation by triggering mitogen-activated protein kinases (MAPKs), which can increase the incidence of cell transformation, the rate of genetic mutations and up-regulate COX-2. The investigators concluded that colonic bacteria such as
S. bovis can contribute to cancer development particularly in chronic infection/inflammation diseases where bacterial components may interfere with cell function [
11].
Bacterial strategies: cell cycle control and toxic warfare
Bacterial toxins can kill cells or at reduced levels alter cellular processes that control proliferation, apoptosis and differentiation. These alterations are associated with carcinogenesis and may either stimulate cellular aberrations or inhibit normal cell controls. Cell-cycle inhibitors, such as cytolethal distending toxins (CDTs) and the cycle inhibiting factor (Cif), block mitosis and are thought to compromise the immune system by inhibiting clonal expansion of lymphocytes. In contrast, cell-cycle stimulators such as the cytotoxic necrotizing factor (CNF) promote cellular proliferation and interfere with cell differentiation [
20].
Bacterial toxins that subvert the host eukaryotic cell cycle have been classified as cyclomodulins. For example, CNF is a cell-cycle stimulator released by certain bacteria, such as
E. coli. CNF triggers G
1 – S transition and induces DNA replication. The number of cells does not increase, however. The cells become multinucleated instead, perhaps by the toxin's ability to inhibit cell differentiation and apoptosis [
63,
64].
Conversely the cytolethal distending toxin (CDT), as previously mentioned, is a cell-cycle inhibitor used by several species of Gram-negative bacteria, including
Campylobacter jejuni and
S. typhi. The CdtB unit of CDT is a DNAse that creates double-stranded DNA breaks causing cell cycle arrest, usually at the G
2 checkpoint [
65]. Cif is a cell cycle inhibitor found in enteropathogenic (EPEC) and enterohaemorrhagic (EHEC)
E. coli. EPEC and EHEC deliver this novel toxin by injecting it into the infected epithelial cells. Cif arrests the cells at the G2/M phase [
66]causing unique alterations in the host cell that result in attachment of the cytoskeleton to the host cell membrane. This anchoring of the cytoskeleton inhibits mitosis, causing cellular and nuclear enlargement. Although DNA synthesis is initiated it does not lead to nuclear division. Endoreduplicaton occurs resulting in cellular DNA content of 8–16n [
20,
66].
In a cell culture study, Haghjoo and Galán [
65] found that
S. typhi produced a unique
cdtB-dependent CDT that required bacterial internalization into host cells. When Cos-2 cells were transfected with
S. typhi the effects of the
cdtB subunit were severe fragmentation of chromatin characteristic of the CdtB subunit of CDT expressed by other species. The authors proposed that
S. typhi subsequent to internalization deviated from the usual endocytic pathway that leads to lysosomes, reaching an unusual membrane-bound compartment where it can survive and replicate. It is possible that this unique CDT may be involved in some aspects of the ability of
S. typhi to cause long, persistent infections in humans, because, at least in other bacteria, this toxin has been shown to possess immunomodulatory activities.
Toxins are not the only strategy for evading the host's immune system, however. An early study by Kilian et al. [
67] reported that some strains of
Capnocytophaga ochracea, an oral pathogen, are capable of hydrolytically degrading immunoglobulin A subclass 1 found in the oral cavity. This property may enhance colonization and invasion of oral lesions which characterize many bacteremias due to
Capnocytophaga species. [
67]. Shurin et al. [
68] obtained evidence that Capnocytophaga species inhibit polymorphonuclear leukocyte migration; a means by which these species may evade phagocytosis.
The immune system may also be evaded by the protection offered by bacterial biofilms. An example of this phenomenon is provided by uropathic
E. coli species whose biofilms protect it from the immune system and making it difficult to treat these infections effectively by antibiotics. This has been demonstrated in bladder infections where the same species is recovered after repeated flare-ups thought to have been cleared by antibiotic therapy, suggesting a subclinical infection that has become chronic [
69].
Bacterial site-specific colonization
Bacterial adherence is thought to be the first important step in colonization. It is now recognized that bacteria bind to and colonize host cells in a highly selective manner via a "lock- and key" mechanism. This selectivity of bacterial adhesion plays an important role in many infectious processes, and an understanding of the mechanisms involved could provide molecular explanations for the innate resistance or susceptibility of hosts and tissues to many infectious agents.
Regulators of complement activation (RCA proteins) prevent the destructive consequences of inappropriate immune activation. Decay-accelerating factor (CD55) is a member of the RCA protein family that protects host cells from complement damage and regulates the classical, alternative and lectin pathways that converge to target cells for destruction in all 3 pathways of the innate immune system [
70]. CD55 is expressed on all serum-exposed cells. Perhaps due to its ubiquitous expression, it is thought that bacterial pathogens, including uropathogenic
Escherichia coli, use CD55 as a receptor prior to infection. Williams et al. [
70] suggested that pathogens have evolved to exploit the cellular roles of this molecule thereby gaining immunological advantage [
70].
The influence on
E. coli binding of the two known single amino acid polymorphisms within short consensus repeat (SCR) domains of CD55 was examined by Pham et al. [
71] and Nowicki et al [
72]. The bacterial strains sensitive to a change in SCR3 were found to be insensitive to changes in SCR4 and vice versa, suggesting that multiple, independent binding sites of CD55 were used by different bacterial strains. Evidence from those investigations suggested that
E. coli strains sensitive to changes in one binding domain were not affected by changes in other domains. Furthermore, the use of CD55 as a receptor by a variety of uropathic
E. coli was found to correlate with symptomatic infections [
71,
72]. Evidence from those investigations indicated the extraordinary degree of site-specific colonization of these closely related strains.
Bacteria associated with a coincidental or diagnostic role
Each year nearly 30,000 Americans are diagnosed with oral cancer [
73,
74]. Over 90% of these malignancies are oral squamous cell carcinoma (OSCC). Despite advances in surgery, radiation and chemotherapy, the five-year survival rate is 54%, one of the lowest of the major cancer sites and this rate has not improved significantly in recent decades [
38,
75,
76]. The disease kills one person every hour – more people than cervical cancer, Hodgkin's disease, or malignant melanoma [
38]. Notably, incidence in young adults (<40 years) is increasing in the U.S. [
8,
10] and worldwide [
9,
77]. The World Health Organization predicts a continuing worldwide increase in oral cancer over the next several decades [
78].
Early detection followed by appropriate treatment, increases cure rates to about 80%, and greatly improves the quality of life by minimizing extensive, debilitating treatments [
75]. Oral cancer is asymptomatic in its early stages, however, and in spite of the accessibility of the oral cavity to direct examination, these malignancies are often not detected until a late stage [
79‐
81]. Oral cancer is unusual in that it carries a high risk of second primary tumors. Patients who survive a first cancer of the oral cavity have up to a 20-fold increased risk of developing a second primary oral cancer. The heightened risk can last 5–10 years, sometimes longer [
82].
In response to the difficulties in effectively treating oral cancer, research studies are focusing on prevention and early diagnostics. Some of these studies have found that OSCC lesions are colonized by an altered microbiota [
83,
84]. Other investigations have found bacterial DNA or live organisms within oral cancer tissues [
85,
86]. The true nature of the relationships between oral bacteria and oral or esophageal cancers is, however, currently unknown.
PCR techniques have been used to seek the DNA of bacterial species in head and neck cancer tissues. Sasaki et al. [
85] found
S. anginosus DNA sequences in tissue samples from 127 cancer patients. Tissues examined included esophageal cancer, gastric cancer tissues, and dysplasia of the esophagus from esophageal cancer patients. No
S. anginosus DNA was found in noncancerous esophagus or stomach samples. However, the degree of
S. anginosus infection in biopsied tissues was much more obvious in the dysplastic and cancerous sections than in the noncancerous portions of the esophagus suggesting that
S. anginosus infection occurred at an early stage of esophageal cancer. The authors suggested that
S. anginosus could play a significant role in the carcinogenic process of most cases of esophageal cancer and some cases of gastric cancer by causing inflammation.
Morita et al. [
86] found that 8 of 18 (44%) samples from the esophagus contained a detectable level of
S. anginosus DNA, but only 5 of 38 (13%) of oral cancer had detectable DNA levels of this organism. The quantity of
S. anginosus DNA in the esophageal cancer tissues was significantly higher than in oral cancer. The maximum amount of
S. anginosus DNA was approximately 10 times higher in esophageal than in oral cancer tissues. In addition, none of the 5 different oral cancer sites (floor of mouth, maxillary or mandibular gingiva, buccal mucosa, and tongue) showed significant signs of
S. anginosus infection. Most non-cancerous tissues of the esophagus and tongue showed an undetectable level of
S. anginosus. The authors concluded that
S. anginosus is associated with esophageal cancer, but is not closely related with oral cancer.
In a previous study by Mager et al. [
87] it was determined that the salivary microbiota was similar to that of the oral soft tissues. Therefore, the investigators examined whether the salivary counts of 40 common oral bacteria in subjects with an oral squamous cell carcinoma (OSCC) lesion would differ from those found in cancer-free (OSCC-free) controls [
83]. Unstimulated saliva samples were collected from 229 OSCC-free and 45 OSCC subjects and evaluated for their content of 40 common oral bacteria using checkerboard DNA-DNA hybridization.
DNA counts per ml saliva were determined for each species, averaged across subjects in the 2 subject groups, and the significance of differences between groups determined using the Mann-Whitney test and adjusted for multiple comparisons. The diagnostic sensitivity and specificity in detection of OSCC by levels of salivary organisms were computed and comparisons made separately between a non-matched group of 45 OSCC subjects and 229 controls and a group of 45 OSCC subjects and 45 controls matched by age, gender and smoking history.
Counts of 3 of the 40 species tested, Capnocytophaga gingivalis, Prevotella melaninogenica and Streptococcus mitis, were elevated in the saliva of individuals with OSCC (p < 0.001). When tested as diagnostic markers the 3 species were found to predict 80% of cancer cases (sensitivity) while excluding 83% of controls (specificity) in the non-matched group. Diagnostic sensitivity and specificity in the matched group were 80% and 82% respectively. These findings suggest that high salivary counts of C. gingivalis, P. melaninogenica and S. mitis could be diagnostic indicators of OSCC.
The reasons for the differences in colonization patterns of specific bacterial species at different host locations are only partially understood. These reasons include differences in nutrient availability, competition among species for binding sites, inter-species antagonisms or cooperations, and the differences in receptors present on different tissues that permit binding by specific adhesins possessed by different species. Other factors that may partly explain the unfavorable microbial shifts observed in oral carcinoma surface biofilms are a compromised host response or the irregularity of the lesion surface providing stagnant habitats.
The most intensely studied of these possibilities has been the specificity in adhesion of different bacterial species to receptors on oral soft tissues. Many studies have focused on fimbriae-mediated adhesion and adhesins in the adherence of different oral species to oral epithelial cells [
88‐
91]. As a universal trait of cancer cells is alterations in cell surface receptors, studies have examined the colonization of healthy and cancerous epithelia [
83,
85‐
87,
92].
A study by Neeser et al. [
92] examined the binding of a common oral bacterial species,
Streptococcus sanguis OMZ 9 to healthy and cancerous buccal cell lines. Results showed that
S. sanguis bound to exfoliated human buccal epithelial cells in a sialic acid-sensitive manner. The desialylation of such cells invariably abolished adhesion of
S. sanguis to the epithelial cell surface. The resialylation of desialylated HBEC with CMP-sialic acid and Galß1,3GalNAc α2,3-sialyltransferase specific for
O-glycans restores the receptor function for
S. sanguis OMZ 9, whereas a similar cell resialylation with the Galß1,4GlcNAc α2,6-sialyltmnsferase specific for
N-glycans is without effect. These findings suggested that a 23 kDa cell surface glycoprotein bearing a carbohydrate sequence, NeuNAc alpha 2-3Gal beta 1-3GalNAc O-linked sugar chains, is recognized by
S. sanguis on exfoliated human buccal epithelial cells. In similar experiments carried out with a buccal carcinoma cell line termed SqCC/Y1,
S. sanguis did not attach in great numbers to cultured tumor cells. These cells were shown to not express the membrane glycoprotein bearing alpha 2,3-sialylated O-linked carbohydrate chains.
Aberrations in the cell surface carbohydrate structures have now been established as a universal characteristic of malignant transformation of cells, and cancer has been referred to as a molecular disease of the cell membrane glycoconjugates [
93,
94]. Thus, changes in the tumor cell surface structure could alter the adhesion of different species of oral bacteria. Notably, even species within the same genera, such as streptococci, have been found to differ in their colonization of healthy and cancerous oral tissues [
83,
87].
Conclusion
Cancer is commonly defined as the uncontrolled growth of abnormal cells that have accumulated enough DNA damage to be freed from the normal restraints of the cell cycle. Several pathogenic bacteria, particularly those that can establish a persistent, infection, can promote or initiate abnormal cell growth by evading the immune system or suppressing apoptosis [
54,
137]. Intracellular pathogens survive by evading the ability of the host to identify them as foreign. Other species or their toxins can alter host cell cycles or stimulate the production of inflammatory substances linked to DNA damage [
120].
The highly site-specific adherence of bacteria involves binding species-specific adhesions to the required cell surface receptors. The role of species that colonize tumors could be causal, coincidental or potentially protective. If adhesion to the tumor in question is highly sensitive and specific it may be ideal not only in diagnosing the presence of a malignancy but also in delivering the appropriate therapy.
The bacterial species associated with cancer etiology are diverse; however, the infections they cause share common characteristics [
18]. The time between acquiring the infection and cancer development is most often years or even decades as seen in cancers associated with
H. pylori,
S. typhi and
S. bovis infections. Chronic interactions between the infective agent and immune response and/or a susceptible host appear to contribute to carcinogenesis [
8,
18,
38,
138]. Preventing or treating the infection may prevent the cancer in question. Notably, the vast majority of individuals infected with a cancer-causing species will not develop cancer [
18].
Evidence suggests that certain individuals are more susceptible to infections linked to cancer development and that the incidence of certain cancers varies among populations. For example, gallbladder cancer is 3 times higher in females as in males in all populations [
26]. Lung cancer is highest in populations that smoke however, only a small proportion of smokers develop lung cancer [
42]. Although colon cancer is the 3
rd highest cancer in the United States, individuals with IBD have a far greater risk of colorectal cancer than individuals without IBD [
56‐
58].
A screening test for oral cancer based on salivary counts of bacterial species is appealing. Currently saliva is meeting the demand for inexpensive, non-invasive, and easy-to-use diagnostic aids for oral and systemic diseases, and for assessing risk behaviors such as tobacco and alcohol use. Although the colonization of certain bacterial species may be coincidental to favorable conditions provided by OSCC, increased numbers of certain salivary species may be clinically useful if shown to be a signature of oral cancer and if sensitivity and specificity are improved.
Successful treatment for cancers was reported by Dr. Coley and others one hundred years ago. His approach of using killed bacterial vaccines was surprisingly effective in some patients even in the latest stages of cancer. Dr. Coley believed that the human immune system had the power to cure cancers if properly stimulated. Today, some investigators agree and have designed new treatments that stimulate the immune system to recognize and target the lesion. Recent reports suggest that attenuated bacterial vaccines can safely and effectively deliver plasmids encoding tumor self antigens. These studies have reported successful treatment of certain cancers and prevention of recurrences [
39,
110,
111]. Cancer vaccines although promising, present significant challenges. These include identification of highly effective bacterial strains and their attenuations, addressing safety issues and the problem of overcoming the peripheral T cell tolerance against tumor self-antigens [
139]. Further, the response to vaccines will likely vary among individuals.
It appears that colonization by certain bacteria may reduce the risk of cancer in some populations. The epidemiological trends of esophageal adenocarcinoma and Helicobacter pylori infection have stimulated research into whether these may be coincidental or due to an inverse association. Intriguing results suggest there is an association represented by a complex continuum that begins with curing infections of virulent strains of H. pylori. The absence of H. pylori appears to elevate ghrelin which stimulates increased appetite in some individuals. High ghrelin levels appear to be associated with increased incidence of obesity. Obesity is reported to be a contributing factor in GORD. Finally, GORD may lead to Barrett's esophagus which increases the risk of esophageal adenocarcinoma. If these relationships can be proven, then the colonization of this species and its seemingly negative association with EA may be more clearly understood.
In summary, recent research has uncovered a great deal of information regarding the bacterial mechanisms used to cause, colonize or cure cancer, however, many questions remain. For example, do the bacteria in question initiate, promote, or merely show affinity for the neoplasm? Conversely does cancer weaken the host which facilitates acquiring the infection? Can the highly site specific colonization of certain bacteria for a tumor be clinically useful in diagnosis or treatment? Could attenuated bacteria be used in vaccines to safely and effectively deliver therapeutic agents? The continued exploration of these questions will bring research ever closer to the prevention, early diagnosis and truly effective treatment of this scourge of mankind.
Competing interests
The author(s) declare that they have no competing interests.